The investment comes from FPE Fund III and will support Clearstate as it expands its geographical reach and go to market capabilities.
"Clearstate is a highly compelling business that aligns perfectly with FPE’s expertise in supporting B2B data and information companies. Operating in a large and dynamic market, Ivy and her team have built Clearstate into a leading provider of essential market data. We are genuinely excited to partner with Ivy and her team, supporting their vision and helping to unlock the significant growth potential ahead."
The round was led by We Venture Capital and Cross-Border Impact Ventures to support the development of liquid biopsy tests.
"The power of the OXcan proteomics biomarker discovery platform and the data generated by Oxcan stand out against the backdrop of other liquid biopsy companies, indicating a truly superior performance in the identification of early stage lung cancer"
The Series A round was co-led by Forbion and General Atlantic to support clinical trials and portfolio expansion.
"People living with obesity and its complications deserve better options at each stage of their treatment journey. These include oral therapies with less frequent dosing regimens, which have the potential for improved efficacy and tolerability, and innovative combination therapies for healthier weight loss and—equally importantly—maintenance of metabolically healthy weight. We created Verdiva Bio to accelerate the development of differentiated medicines that address these significant unmet medical needs."
The round was led by We Venture Capital and Cross-Border Impact Ventures to fund the global commercialisation of its liquid biopsy technology.
"Having developed blood-based proteomic tests for lung cancer for over two decades, I appreciate the difficulty of detecting cancers early through liquid biopsy. Convinced that OXcan’s unique approach can address this clinical need, I feel privileged to join the team. Together, our plan is to offer this novel technological approach to large markets worldwide to start a new era of early detection and improve patient outcomes."
— Heinrich Roder, Senior Vice President of Research and Development
LDV Capital led the pre-seed round, with backing from Bek Ventures and Tiny Supercomputer Investment Company, to fund platform expansion and hospital deployments.
"The Royal Orthopaedic Hospital is known as one of the UK’s leading institutions in terms of outcomes and efficiency and, naturally, they have decided to utilize our platform and leverage the cutting-edge AI technology to even further increase the efficiency of surgical procedures. By autonomously tracking surgical processes and tools, VitVio minimizes the potential for human error and adds no extra steps to the surgical process, aligning with industry experts’ consensus on the importance of non-intrusive technology."
